AR066473A1 - Compuesto de triazolil aminopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar cancer - Google Patents
Compuesto de triazolil aminopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar cancerInfo
- Publication number
- AR066473A1 AR066473A1 ARP080101932A ARP080101932A AR066473A1 AR 066473 A1 AR066473 A1 AR 066473A1 AR P080101932 A ARP080101932 A AR P080101932A AR P080101932 A ARP080101932 A AR P080101932A AR 066473 A1 AR066473 A1 AR 066473A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino
- ethyl
- methyl
- hydroxy
- alkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- -1 Triazolyl aminopyrimidine compound Chemical class 0.000 abstract 21
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- 239000000460 chlorine Chemical group 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 abstract 1
- 208000017604 Hodgkin disease Diseases 0.000 abstract 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 abstract 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 abstract 1
- 208000033781 Thyroid carcinoma Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002357 endometrial effect Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuesto de triazolil aminopirimidina de la formula (1), donde R1 es metilo, metoxi, hidroxi, amino, cloro, amino(alquilo C1-4), dietilamino(alquilo C1-2), (alquil C1-2)amino(alquilo C1-2), aminocarbonil(alquilo C1-3), 1-((1-amino)etilcarbonilamino)etilo, 2-(N- metilamino)etoxi, 2-cianoprop-2-ilo, (2-hidroxi-2-metil)-1-propiloxi, (2-hidroxi)etilaminocarbonilmetilo, (1-fluoro)-(2-amino)etilo, (1-fluoro)-(1-metil)-(2-amino)etilo, difluorometilo, 1-((2,2-difluoro)etilamino)etilo, difluorometilcarbonilo, trifluorometilcarbonilo, (1-amino)-(2,2,2-trifluoro)etilo, (1-metilamino)-(22,2-trifluoro)etilo, (1-hidroxi)-(2,2,2-trifluoro)etilo, 2-(amino)etoxi, 2-(hidroxi)etoxi, 1-((N-(2-hidroxi)etil)-(N-metil)-amino)(alquilo C1-2), 4-(hidroxi)piperidin-1-iI-metilo, 1-(piperazin-1-iI)etilo, 2-(hidroxi)etilsulfonilo, 1-(amino)ciclopropilo, 1-(metilamino)ciclopropilo, 1-amino(ciclobutilo), 1-aminociclopent-2-ilo, ciclopentanon-2-ilo, tetrahidrofur-2-ilo,pirrolidin-2-ilo, azaridin-2-ilo, o (morfolin-4-ilo)metilo, R2 es hidrogeno o amino, siempre que si R2 es amino, R1 y R2 forman un anillo pirrol fusionado al fenilo; o si R1 es amino, R1 y R2 pueden formar ya sea un anillo pirrol o piridinafusionado al fenilo; R3 es hidrogeno, cloro o fluoro; R4 es hidrogeno, metilo, cloro o fluoro; R5 es hidrogeno, hidroximetilo o metilo; y R6 es hidrogeno, hidroximetilo o metilo; o una sal del mismo farmacéuticamente aceptable. Composicionfarmacéutica que lo comprende. Uso de dichos compuestos para preparar un medicamento util para tratar cáncer de pulmon de células no pequenas, orofaríngeo, esofageal, gástrico, melanoma, carcinoma epidermoide de la piel, mama, ovario, endometrial,colorrectal, neuroglioma, glioblastoma, carcinoma de tiroides, cervical, pancreático, prostata, hapatoblastoma y linfoma de Hodgkin.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93834707P | 2007-05-16 | 2007-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066473A1 true AR066473A1 (es) | 2009-08-19 |
Family
ID=39951591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101932A AR066473A1 (es) | 2007-05-16 | 2008-05-07 | Compuesto de triazolil aminopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8063035B2 (es) |
| EP (1) | EP2155734A2 (es) |
| JP (1) | JP5248600B2 (es) |
| KR (1) | KR101131261B1 (es) |
| CN (1) | CN101679395B (es) |
| AR (1) | AR066473A1 (es) |
| AU (1) | AU2008254319B2 (es) |
| BR (1) | BRPI0811433A2 (es) |
| CA (1) | CA2691997A1 (es) |
| CL (1) | CL2008001323A1 (es) |
| EA (1) | EA016781B1 (es) |
| MX (1) | MX2009012228A (es) |
| PE (1) | PE20090216A1 (es) |
| TW (1) | TW200908981A (es) |
| WO (1) | WO2008144223A2 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964729B2 (en) | 2006-08-28 | 2011-06-21 | Massachusetts Institute Of Technology | Sox-based kinase sensor |
| SI2125794T1 (sl) | 2006-12-21 | 2011-02-28 | Lilly Co Eli | Spojine imidazolidinonil aminopirimidina za zdravljenje raka |
| AU2007334039B2 (en) | 2006-12-21 | 2012-02-16 | Eli Lilly And Company | Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer |
| US8440835B2 (en) | 2007-02-26 | 2013-05-14 | Massachusetts Institute Of Technology | Environmentally sensitive fluorophores |
| AU2008254318B2 (en) * | 2007-05-16 | 2012-04-05 | Eli Lilly And Company | Triazolyl aminopyrimidine compounds |
| WO2008144223A2 (en) | 2007-05-16 | 2008-11-27 | Eli Lilly And Company | Triazolyl aminopyrimidine compounds |
| KR101123178B1 (ko) * | 2009-04-09 | 2012-06-13 | (주)에스메디 | 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 |
| JP2013502901A (ja) * | 2009-08-25 | 2013-01-31 | オンコセラピー・サイエンス株式会社 | がんの治療および診断の標的遺伝子としてのercc6l |
| WO2011025546A1 (en) * | 2009-08-31 | 2011-03-03 | Massachusetts Institute Of Technology | 1, 2, 3-triazole containing protein kinase sensors |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| US9611201B2 (en) * | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
| WO2017220516A1 (en) * | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives |
| US11084829B2 (en) | 2018-09-24 | 2021-08-10 | Rapt Therapeutics, Inc. | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof |
| CN114616227B (zh) * | 2019-09-05 | 2025-01-21 | 墨尔本大学 | 硝化抑制剂 |
| CN112341428A (zh) * | 2020-11-04 | 2021-02-09 | 菏泽鸿特药业有限公司 | 一种噻吩-2-乙胺的生产方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929726A (en) * | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
| WO2004063192A1 (en) | 2003-01-10 | 2004-07-29 | Pharmacopeia Drug Discovery, Inc. | Imidazolyl pyrimidine derivatives useful as il-8 receptor modulators |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| CA2534127A1 (en) * | 2003-07-31 | 2005-02-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzothiophene compounds and uses thereof |
| WO2006066172A1 (en) * | 2004-12-17 | 2006-06-22 | Amgen, Inc. | Aminopyrimidine compounds and methods of use |
| TW200800201A (en) | 2005-11-18 | 2008-01-01 | Lilly Co Eli | Pyrimidinyl benzothiophene compounds |
| CN101437519A (zh) | 2006-03-31 | 2009-05-20 | 艾博特公司 | 吲唑化合物 |
| AU2007334039B2 (en) | 2006-12-21 | 2012-02-16 | Eli Lilly And Company | Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer |
| SI2125794T1 (sl) * | 2006-12-21 | 2011-02-28 | Lilly Co Eli | Spojine imidazolidinonil aminopirimidina za zdravljenje raka |
| AU2008254318B2 (en) * | 2007-05-16 | 2012-04-05 | Eli Lilly And Company | Triazolyl aminopyrimidine compounds |
| WO2008144223A2 (en) | 2007-05-16 | 2008-11-27 | Eli Lilly And Company | Triazolyl aminopyrimidine compounds |
-
2008
- 2008-05-07 WO PCT/US2008/062808 patent/WO2008144223A2/en not_active Ceased
- 2008-05-07 AU AU2008254319A patent/AU2008254319B2/en not_active Ceased
- 2008-05-07 CA CA002691997A patent/CA2691997A1/en not_active Abandoned
- 2008-05-07 TW TW097116886A patent/TW200908981A/zh unknown
- 2008-05-07 EP EP08747731A patent/EP2155734A2/en not_active Withdrawn
- 2008-05-07 JP JP2010508500A patent/JP5248600B2/ja not_active Expired - Fee Related
- 2008-05-07 CL CL2008001323A patent/CL2008001323A1/es unknown
- 2008-05-07 MX MX2009012228A patent/MX2009012228A/es active IP Right Grant
- 2008-05-07 US US12/598,926 patent/US8063035B2/en not_active Expired - Fee Related
- 2008-05-07 BR BRPI0811433A patent/BRPI0811433A2/pt not_active IP Right Cessation
- 2008-05-07 EA EA200971068A patent/EA016781B1/ru not_active IP Right Cessation
- 2008-05-07 PE PE2008000798A patent/PE20090216A1/es not_active Application Discontinuation
- 2008-05-07 AR ARP080101932A patent/AR066473A1/es unknown
- 2008-05-07 KR KR1020097023340A patent/KR101131261B1/ko not_active Expired - Fee Related
- 2008-05-07 CN CN2008800157689A patent/CN101679395B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EA200971068A1 (ru) | 2010-04-30 |
| KR20090130242A (ko) | 2009-12-21 |
| TW200908981A (en) | 2009-03-01 |
| BRPI0811433A2 (pt) | 2016-03-22 |
| CN101679395B (zh) | 2012-06-13 |
| CN101679395A (zh) | 2010-03-24 |
| US20100087431A1 (en) | 2010-04-08 |
| PE20090216A1 (es) | 2009-02-28 |
| CA2691997A1 (en) | 2008-11-27 |
| CL2008001323A1 (es) | 2009-05-29 |
| EP2155734A2 (en) | 2010-02-24 |
| JP2010527365A (ja) | 2010-08-12 |
| WO2008144223A2 (en) | 2008-11-27 |
| AU2008254319A1 (en) | 2008-11-27 |
| KR101131261B1 (ko) | 2012-04-24 |
| WO2008144223A3 (en) | 2009-02-05 |
| AU2008254319B2 (en) | 2012-04-19 |
| MX2009012228A (es) | 2009-12-01 |
| US8063035B2 (en) | 2011-11-22 |
| EA016781B1 (ru) | 2012-07-30 |
| JP5248600B2 (ja) | 2013-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066473A1 (es) | Compuesto de triazolil aminopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar cancer | |
| CY1122883T1 (el) | Ν-((4,6-διμεθυλ-2-οξο-l,2-διυδροπυριδιν-3-υλ)μεθυλ)-5-(αιθυλ (τετραϋδρο-2η-πυραν-4-υλ)αμινο)-4-μεθυλ-4'-(μορφολινομεθυλ)-[l,1'-διφαινυλ]-3-καρβοξαμιδιο υδροβρωμικο για χρηση στη θεραπεια μιας κυτταροπολλαπλασιαστικης διαταραχης του αιματολογικου συστηματος | |
| PH12019501874B1 (en) | Crystal modifications | |
| AR071187A1 (es) | Compuesto de arilmetil-tiazinamina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento para el tratamiento de la enfermedad de alzheimer | |
| CL2009000882A1 (es) | Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer. | |
| BR112012023660B8 (pt) | usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer | |
| CL2008002294A1 (es) | Compuestos derivados de benzotiazol acetamida y sus sales farmaceuticamente aceptables; composicion farmaceutica de dichos compuestos; su uso para tratar enfermedades mediadas por pi3 quinasa incluyendo melanoma, carcinoma y otras condiciones derivadas del cancer. | |
| UA104585C2 (ru) | Композиция, содержащая антитело, которое связывается с доменом ii her2, и его кислые варианты | |
| BR112015011036A2 (pt) | derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais | |
| MX384521B (es) | Compuestos de benceno substituidos con arilo o heteroarilo. | |
| ECSP099044A (es) | Compuestos de pirimido fusionados | |
| BR112015008311A2 (pt) | conjugados fármaco-proteína | |
| BRPI0714315B8 (pt) | arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende | |
| TN2012000316A1 (en) | Fused heteroaromatic pyrrolidinones as syk inhibitors | |
| CL2007001882A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
| HN2009000455A (es) | Inhibidore de quinasa | |
| EA201290394A1 (ru) | Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7 | |
| CL2007001881A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
| CL2010001468A1 (es) | Compuestos derivados de adamantildiamida, moduladores alostericos del receptor 5 glutamato metabotropico (mglur5); composicion farmaceutica que los comprende; y uso para tratar una enfermedad o trastorno del snc tal como depresion, ansiedad, esquizofrenia y enfermedad de parkinson. | |
| PE20141148A1 (es) | Mesilato de n-[5-(aminosulfonil)-4 metil-1-3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato | |
| AR083417A1 (es) | Composiciones farmaceuticas que contienen un dgat1 inhibidor | |
| EA201270428A1 (ru) | Замещенные n-фенил-1-(4-пиридинил)-1н-пиразол-3-амины | |
| MX2024012124A (es) | Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos. | |
| NZ704023A (en) | Novel rebamipide prodrug, method for producing same, and usage thereof | |
| SG158091A1 (en) | Imidazoazepinone compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |